Researchers conducted a study at the University of Michigan and found that androgen deprivation therapy, delivered via injections or surgical castration, resulted in a 30-40 percent increase in risk for colorectal cancer, according to a news release.
Androgen deprivation therapy is often prescribed as a prostate cancer treatment for low-risk prostate cancer patients and has already come under scrutiny for causing increased risk of cardiovascular disease and other heart conditions.
Despite the seemingly alarming findings, the absolute risk for colorectal cancer is no more than 2.5 percent over a five-year period.
Read the news release about androgen deprivation therapy and CRC.
Read other coverage about colorectal cancer:
- Virtual colonoscopy a Possibility for Increased Patient Comfort
- AGA: Testing Between Colonoscopies Can Help Patients With High Risk of CRC
- CDC: 50% of CRC Cases Are Detected in Late Stages
Androgen deprivation therapy is often prescribed as a prostate cancer treatment for low-risk prostate cancer patients and has already come under scrutiny for causing increased risk of cardiovascular disease and other heart conditions.
Despite the seemingly alarming findings, the absolute risk for colorectal cancer is no more than 2.5 percent over a five-year period.
Read the news release about androgen deprivation therapy and CRC.
Read other coverage about colorectal cancer:
- Virtual colonoscopy a Possibility for Increased Patient Comfort
- AGA: Testing Between Colonoscopies Can Help Patients With High Risk of CRC
- CDC: 50% of CRC Cases Are Detected in Late Stages